Breakdown | ||||
Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
158.19M | 90.39M | 80.51M | 66.63M | 20.74M | Gross Profit |
27.89M | 23.34M | 20.08M | 16.25M | 5.71M | EBIT |
-787.00K | 3.33M | 2.34M | 3.44M | 1.97M | EBITDA |
384.00K | 5.87M | 5.61M | 5.90M | 804.93K | Net Income Common Stockholders |
-12.49M | -1.70M | -111.51K | 1.50M | 27.92K |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
1.50M | 1.15M | 5.12M | 2.68M | 1.23M | Total Assets |
73.72M | 56.71M | 57.09M | 39.13M | 8.72M | Total Debt |
49.85M | 27.27M | 22.84M | 12.30M | 2.73M | Net Debt |
48.36M | 26.12M | 17.71M | 9.62M | 1.50M | Total Liabilities |
69.64M | 40.27M | 38.62M | 21.81M | 4.85M | Stockholders Equity |
4.08M | 16.44M | 18.47M | 17.32M | 3.87M |
Cash Flow | Free Cash Flow | |||
3.02M | -3.20M | 3.38M | 24.13K | 479.20K | Operating Cash Flow |
5.93M | -1.27M | 4.04M | 1.97M | 804.89K | Investing Cash Flow |
-26.43M | -3.33M | -12.67M | -16.08M | 894.94K | Financing Cash Flow |
20.85M | 625.00K | 11.07M | 15.56M | -424.55K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
67 Neutral | $982.82M | 17.18 | 3.80% | ― | 35.87% | ― | |
56 Neutral | $988.67M | ― | -23.33% | ― | 0.67% | 19.14% | |
54 Neutral | C$139.89M | ― | -23.20% | ― | -8.80% | 26.77% | |
52 Neutral | $5.35B | 3.96 | -42.60% | 2.86% | 17.58% | 1.27% | |
50 Neutral | C$4.16M | ― | -160.58% | ― | 44.96% | -827.30% | |
47 Neutral | C$335.02M | ― | -84.50% | ― | -16.27% | ― |
Premier Health of America Inc. announced that all matters proposed at its annual general meeting on April 30, 2025, were approved by shareholders. Key decisions included the re-appointment of Raymond Chabot Grant Thornton LLP as auditor, the election of board members Pierre-Luc Toupin, Hubert Marleau, and Jean-Robert Pronovost, and the continuation of the incentive Stock Option Plan. The meeting saw participation from shareholders holding 54.49% of the total issued and outstanding shares, indicating strong stakeholder engagement and support for the company’s strategic direction.
Spark’s Take on TSE:PHA Stock
According to Spark, TipRanks’ AI Analyst, TSE:PHA is a Neutral.
Premier Health of America Inc faces significant financial and operational challenges, as evidenced by declining revenue, high leverage, and a negative P/E ratio. Although there are some positive cash flow aspects and management’s proactive steps to improve efficiency, these are overshadowed by the broader financial difficulties and bearish technical indicators.
To see Spark’s full report on TSE:PHA stock, click here.
Premier Health of America Inc. reported a challenging first quarter for 2025, with revenues declining to $32.1 million from $37 million in the same period the previous year. The company faced a net loss of $2.3 million, largely due to decreased adjusted EBITDA and increased financial expenses. The implementation of Quebec’s Bill 10, which imposes restrictions on independent labor, significantly impacted the Per Diem segment, now representing only 5% of revenues. Despite these challenges, the company is actively reorganizing its Quebec operations, reducing workforce, and terminating office leases to improve cost efficiency. The CEO remains optimistic about future improvements in operational efficiency and cost reduction.